OncoMatch/Clinical Trials/NCT04762199
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Is NCT04762199 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Flt3/MerTK Inhibitor MRX-2843 and Osimertinib for advanced lung non-small cell carcinoma.
Treatment: Flt3/MerTK Inhibitor MRX-2843 · Osimertinib — This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR
activating EGFR mutation including typical and atypical mutations in egfr exons 19 and 21
Required: EGFR T790M
If not previously treated with osimertinib, must be EGFR-T790M negative as confirmed using a standard testing platform (circulating tumor deoxyribonucleic acid [ctDNA] or tissue based testing) prior to study treatment
Disease stage
Required: Stage IV, IVA, IVB
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Cannot have received: radiation therapy
Exception: within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Cannot have received: investigational agent
Patients who are receiving any other investigational agents
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3; Hemoglobin ≥ 8.5 g/dL (must be > 2 weeks post-red blood cell transfusion)
Kidney function
Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min (Cockcroft and Gault equation)
Liver function
Bilirubin ≤ 1.5 x ULN (≤ 3.0 mg/dL for Gilbert's disease, ≤ 2.5 x ULN for liver metastases); ALT and AST ≤ 3 x ULN (≤ 5 x ULN for liver metastases)
Cardiac function
QTc interval ≤ 500 msec (average of 3 readings); no known cardiomyopathy or LVEF < 50%
Absolute neutrophil count ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3; Hemoglobin ≥ 8.5 g/dL (must be > 2 weeks post-red blood cell transfusion); Bilirubin ≤ 1.5 x ULN (≤ 3.0 mg/dL for Gilbert's disease, ≤ 2.5 x ULN for liver metastases); Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min; ALT and AST ≤ 3 x ULN (≤ 5 x ULN for liver metastases); QTc interval ≤ 500 msec (average of 3 readings); no known cardiomyopathy or LVEF < 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04762199 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiation therapy, investigational agent disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR T790M is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV or IVA or IVB is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify